

## Fragmentation at Electron Impact of Nitro Derivatives of 1,2,4-Oxadiazole and 1,2,3-Triazole

A.G. Tyrkov, N.A. Solov'ev, T.D. Ladyzhnikova, and K.V. Altukhov

Astrakhan State University, Astrakhan, 414056 Russia  
e-mail: tyrkov@mail.ru


Received April 15, 2003

**Abstract**—Mass spectra were investigated of a series of 3-aryl-5-(nitromethyl)-1,2,4-oxadiazole derivatives and of *N*-methylated (benzylated) isomeric 4-(dinitromethyl)-1,2,3-triazoles. The principal fragmentation processes of these compounds involve the heterocycle opening and/or liberation of nitrogen-containing fragments followed by formation of the most stable fragment ions.

Heterocyclic compounds originating from 1,2,4-oxadiazole and 1,2,3-triazole found recently extensive application as biologically active compounds. Phenoxy-methyl derivatives of 1,2,4-oxadiazole possess anti-ischemic and antiarrhythmic activity [1], oxadiazole sulfamide and hydrazine derivatives are characterized by antimycobacterial activity [2]. Nitrofuryl and imidazole derivatives of oxadiazole are effective against *Staphylococcus aureus* [3] and their application is also suggested as antihistomastic drugs [4]. Among derivatives of 4-nitromethyl 1,2,3-triazole derivatives were found compounds with fungicidal, herbicidal [5], and growth-regulating activity [6]. The wide range of application calls attention also to the mass spectra of this class compounds. Quite a number of publications describes the dissociative ionization of 1,2,4-oxadiazoles and 1,2,3-triazoles under electron impact [7–13]. Mass spectra were investigated of amino- [7, 8] and alkyl-substituted oxadiazoles [9], 1,2,4-oxadiazole indolyl derivatives [10], oxadiazolylpyrazines [11], diphenyl and triphenyl derivatives of 1,2,3-triazoles [12, 13]. Yet the information on the mass spectra of polynitromethyl derivatives of 1,2,4-oxadiazoles and 1,2,3-triazoles is virtually lacking in the literature.

In this study we investigated the pathways of dissociative fragmentation at electron impact of series of 3-aryl-5-(nitromethyl)-1,2,4-oxadiazole derivatives I–V and 4-(dinitromethyl)-1,2,3-triazole derivatives VI–XI shown on Schemes 1 and 2.

The objects for the study were selected in order to get comparative data on fragmentation of oxadiazoles



Ar = 3-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub> (I, V), 4-BrC<sub>6</sub>H<sub>4</sub> (II), 2-MeO-3,5-Cl<sub>2</sub>C<sub>6</sub>H<sub>2</sub> (III), 4-MeOC<sub>6</sub>H<sub>4</sub> (IV); R = C(NO<sub>2</sub>)<sub>2</sub>Cl (I), C(NO<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>Et (II), C(NO<sub>2</sub>)ClCO<sub>2</sub>Et (III, IV), C(NO<sub>2</sub>)<sub>3</sub> (V); R<sup>1</sup> = C(NO<sub>2</sub>)<sub>3</sub> (VI, VIII, IX, XI), C(NO<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>Et (VII, X); R<sup>2</sup> = H (VI, VII, IX, X), Ph (VIII, XI); R<sup>3</sup> = Me (VI, VII, IX, X), CH<sub>2</sub>Ph (VIII, XI).

and triazoles and to discover diagnostic peaks for identification of polynitromethyltriazole isomers.

Mass spectra of oxadiazoles I–V contained peaks of molecular ions  $M^+$  of low intensity (7–12 rel%) and in some cases also peaks of ions  $[M - H]^+$ . Further fragmentation of  $M^+$  involved a cleavage of the oxadiazole ring, ejection of the nitromethyl substituent, and elimination of nitrogen-containing fragments (Scheme 1). In the series of compounds I–V under investigation among the most favorable processes of the primary dissociative ionization of  $M^+$  the reactions of retro-1,3-dipolar cyclization are worth mentioning, and also the cleavage of the nitromethyl substituent from the azole ring. The retro-1,3-dipolar cyclization took three main routes: with the rupture of O–C<sup>5</sup> and C<sup>3</sup>–N<sup>4</sup> bonds (path *a*), O–N<sup>1</sup> and C<sup>3</sup>–N<sup>4</sup> bonds (path *b*), or O–N<sup>1</sup> and N<sup>4</sup>–C<sup>5</sup> bonds (path *c*). This conclusion is supported by the presence of sufficiently intense peaks from arising


## Mass spectra of 3-aryl-5-(nitromethyl)-1,2,4-oxadiazoles I–V and 4-(dinitromethyl)-1,2,3-triazoles VI–XI

Compd. no.	<i>m/z</i> ( <i>I</i> <sub>rel.</sub> , %)
I	328 (8.2) [ <i>M</i> ] <sup>+</sup> , 327 [ <i>M</i> –H] <sup>+</sup> , 313 (1.1), 273 (1.9), 264 (1.8), 250 (1.9), 223 (3), 221 (14.9), 207 (7), 205 (16.2), 190 (31.6) [ <i>M</i> –R] <sup>+</sup> Φ <sub>7</sub> , 182 (27.4) Φ <sub>4</sub> , 179 (6), 168 (26.7) (RCO <sup>+</sup> ) Φ <sub>6</sub> , 167 (28) Φ <sub>2</sub> , 165 (42.3) (ArCNO <sup>+</sup> ) Φ <sub>1</sub> , 162 (44) (ArCN <sub>2</sub> <sup>+</sup> ) Φ <sub>5</sub> , 155 (21.4), 153 (29), 149 (100) (ArCN <sup>+</sup> ) Φ <sub>3</sub> , 140 (2.8), 136 (12.7) (ArN <sup>+</sup> ), 134 (96) (ArC <sup>+</sup> ), 125 (12.7), 122 (6.8) (Ar <sup>+</sup> ), 111 (15), 102 (33.8), 90 (9.4), 76 (12), 75 (27.4), 63 (5), 52 (7.5), 50 (15), 46 (73) (NO <sub>2</sub> <sup>+</sup> ), 30 (31.5) (NO <sup>+</sup> )
II	399 (11.5) [ <i>M</i> ] <sup>+</sup> , 398 (3.8) [ <i>M</i> –H] <sup>+</sup> , 328 (15), 331 (8.5), 282 (18), 252 (21), 222 (35) [ <i>M</i> –R] <sup>+</sup> Φ <sub>7</sub> , 220 (33) Φ <sub>4</sub> , 205 (41) (RCO <sup>+</sup> ) Φ <sub>6</sub> , 204 (32) (R–CN <sup>+</sup> ) Φ <sub>2</sub> , 199 (28.7) (ArCNO <sup>+</sup> ) Φ <sub>1</sub> , 196 (62) (ArCN <sub>2</sub> <sup>+</sup> ) Φ <sub>5</sub> , 190 (4), 183 (100) (ArCN <sup>+</sup> ) Φ <sub>3</sub> , 171 (8), 168 (6.3) (ArC <sup>+</sup> ), 156 (13) (Ar <sup>+</sup> ), 155 (9), 143 (5), 127 (25), 116 (7.5), 102 (48.7), 90 (4), 76 (2.6), 63 (22.5), 50 (40), 46 (75.5) (NO <sub>2</sub> <sup>+</sup> ), 30 (37) (NO <sup>+</sup> )
III	409 (12.5) [ <i>M</i> ] <sup>+</sup> , 374 (11.8), 326 (21), 261 (18.2), 243 (33) [ <i>M</i> –R] <sup>+</sup> Φ <sub>7</sub> , 235 (17), 219 (26.4) (ArCNO <sup>+</sup> ) Φ <sub>1</sub> , 213(34) (ArCN <sub>2</sub> <sup>+</sup> ) Φ <sub>5</sub> , 210 (29.3) Φ <sub>4</sub> , 203 (100) (ArCN <sup>+</sup> ) Φ <sub>3</sub> , 195 (31) (RCO <sup>+</sup> ) Φ <sub>6</sub> , 194 (27) (RCN <sup>+</sup> ) Φ <sub>2</sub> , 190 (14.2) (ArN <sup>+</sup> ), 188 (13) (ArC <sup>+</sup> ), 176 (19.5) (Ar <sup>+</sup> ), 174 (10), 157 (23.3), 146 (14), 123 (15.5), 96 (37), 82 (42), 72 (8.4), 61 (21), 56 (8.7), 46(8.5) (NO <sub>2</sub> <sup>+</sup> ), 35 (11.3) (Cl <sup>+</sup> ), 30 (6.2) (NO <sup>+</sup> )
IV	340 (21.5) [ <i>M</i> ] <sup>+</sup> , 339 (6.1) [ <i>M</i> –H] <sup>+</sup> , 271 (2.6), 261 (9.2), 259 (31.4), 257 (36.6), 233 (11.7), 231 (14.2), 217 (18.7), 210 (21) Φ <sub>4</sub> , 195 (23.4) (RCO <sup>+</sup> ) Φ <sub>6</sub> , 194 (38) (RCN <sup>+</sup> ) Φ <sub>2</sub> , 177 (9.1), 173 (35) [ <i>M</i> –R] <sup>+</sup> Φ <sub>7</sub> , 150 (34) (ArCNO <sup>+</sup> ) Φ <sub>1</sub> , 147 (60.5) (ArCN <sub>2</sub> <sup>+</sup> ) Φ <sub>5</sub> , 134 (100) (ArCN <sup>+</sup> ) Φ <sub>3</sub> , 121 (6.1) (ArN <sup>+</sup> ), 119 (7.9) (ArC <sup>+</sup> ), 107 (13.2) (Ar <sup>+</sup> ), 103 (29.2), 90 (37.6), 77 (45), 64 (39), 57 (11.5), 50 (41.7), 46 (14) (NO <sub>2</sub> <sup>+</sup> ), 35 (4.5) (Cl <sup>+</sup> ), 30 (1.3) (NO <sup>+</sup> )
V	398 (8.8) [ <i>M</i> ] <sup>+</sup> , 193 (26) Φ <sub>4</sub> , 190 (32) [ <i>M</i> –R] <sup>+</sup> Φ <sub>7</sub> , 178 (27.2) (RCO <sup>+</sup> ) Φ <sub>6</sub> , 177 (31) Φ <sub>2</sub> , 165 (48) (ArCNO <sup>+</sup> ) Φ <sub>1</sub> , 163 (6), 162 (32) (ArCN <sub>2</sub> <sup>+</sup> ) Φ <sub>5</sub> , 150 (3.5), 149 (100) (ArCN <sup>+</sup> ) Φ <sub>3</sub> , 137 (9.4) (ArN <sup>+</sup> ), 135 (5.2) (ArC <sup>+</sup> ), 123 (6.0) (Ar <sup>+</sup> ), 114 (24.4), 102 (12.2), 88 (19.5), 76 (43.9), 70 (24), 62 (19), 50 (34), 46 (86) (NO <sub>2</sub> <sup>+</sup> ), 39 (17), 30 (44) (NO <sup>+</sup> )
VI	186 (0.9) [ <i>M</i> –NO <sub>2</sub> ] <sup>+</sup> Φ <sub>1</sub> , 110 (2.5) [ <i>M</i> –2NO <sub>2</sub> –NO] <sup>+</sup> Φ <sub>2</sub> , 108 (1.8), 83 (1.4), 54 (1.5), 53 (2.1), 46 (3) (NO <sub>2</sub> <sup>+</sup> ), 44 (5.8), 43 (1.4) (MeN <sub>2</sub> <sup>+</sup> ) Φ <sub>3</sub> , 42 (1.4), 39 (1.5), 38 (1.5), 30 (100) (NO <sup>+</sup> ), 29 (3.5)
VII	213 (14.4) [ <i>M</i> –NO <sub>2</sub> ] <sup>+</sup> Φ <sub>1</sub> , 198 (1.4), 185 (1.4), 156 (3.6), 155 [ <i>M</i> –NO <sub>2</sub> –NO–CO] <sup>+</sup> (66), 138 (8), 110 (18) [ <i>M</i> –NO <sub>2</sub> –NO–CO <sub>2</sub> Et] <sup>+</sup> Φ <sub>2</sub> , 94 (33), 93 (6.5), 83 (5), 82 (6.5), 68 (5), 67 (40.5), 66 (47), 55 (16), 53 (44), 51 (1.4), 46 (NO <sub>2</sub> <sup>+</sup> ) (2.5), 43 (6.7) (MeN <sub>2</sub> <sup>+</sup> ) Φ <sub>3</sub> , 42 (100) (MeNCH <sup>+</sup> ), 39 (18.6), 30 (7.2) (NO <sup>+</sup> ), 29 (58), 27 (33)
VIII	383 (3.2) [ <i>M</i> ] <sup>+</sup> , 340 (2), 339 (22), 337 (100) [ <i>M</i> –NO <sub>2</sub> ] <sup>+</sup> Φ <sub>5</sub> , 292 (2.6) [ <i>M</i> –C <sub>7</sub> H <sub>7</sub> ] <sup>+</sup> , 247 (2.1) [ <i>M</i> –NO <sub>2</sub> –C <sub>7</sub> H <sub>7</sub> ] <sup>+</sup> , 233 (3.2) [ <i>M</i> –C(NO <sub>2</sub> ) <sub>3</sub> ] <sup>+</sup> , 218 (3.5), 217 (5.1), 204 (3.2), 195 (2), 194 (16) (PhCNCH <sub>2</sub> Ph <sup>+</sup> ), 191 (2.6), 189 (2.2), 180 (4.1), 178 (1.6), 165 (1.6), 157 (1.9), 129 (4.9), 115 (3.2), 106 (3.2), 105 (3), 92 (19), 91 (62) (C <sub>7</sub> H <sub>7</sub> <sup>+</sup> ) Φ <sub>4</sub> , 89 (2.6), 77 (2.2), 65 (11), 51 (1.4), 30 (1.4) (NO <sup>+</sup> )
IX	186 (1.8) [ <i>M</i> –NO <sub>2</sub> ] <sup>+</sup> Φ <sub>1</sub> , 141 (1.1), 124 (1.6), 110 (3.3) [ <i>M</i> –2NO <sub>2</sub> –NO] <sup>+</sup> Φ <sub>2</sub> , 108 (4.9), 83 (4.3), 81 (2.6), 69 (1.4), 56 (1.4), 53 (3.2), 52 (2.6), 45 (5.5), 43 (21) (MeN <sub>2</sub> <sup>+</sup> ) Φ <sub>3</sub> , 42 (3.3), 41 (1.6), 40 (1.8), 39 (3.4), 38 (4.4), 30 (100) (NO <sup>+</sup> ), 29 (5.6)
X	213 (6.5) [ <i>M</i> –NO <sub>2</sub> ] <sup>+</sup> Φ <sub>1</sub> , 168 (1.4), 124 (2.8), 123 (1.7), 111 (3.9), 110 (97) [ <i>M</i> –NO <sub>2</sub> –NO–CO <sub>2</sub> Et] <sup>+</sup> Φ <sub>2</sub> , 96 (1.4), 83 (6.4), 68 (2.5), 57 (1.4), 55 (2), 53 (2), 51 (1.4), 46 (21) (NO <sub>2</sub> <sup>+</sup> ), 44 (3), 43 (27) (MeN <sub>2</sub> <sup>+</sup> ) Φ <sub>3</sub> , 42 (1.5) (MeNCH <sup>+</sup> ), 41 (2), 39 (2.8), 31 (2), 30 (100) (NO <sup>+</sup> ), 29 (40)
XI	383 (0.2) [ <i>M</i> ] <sup>+</sup> , 337 (2) [ <i>M</i> –NO <sub>2</sub> ] <sup>+</sup> Φ <sub>5</sub> , 292 (1) [ <i>M</i> –C <sub>7</sub> H <sub>7</sub> ] <sup>+</sup> , 157 (1.6), 105 (2), 104 (1.9) (PhCN <sup>+</sup> ), 91 (59) (C <sub>7</sub> H <sub>7</sub> <sup>+</sup> ) Φ <sub>4</sub> , 89 (1.6), 77 (4.4), 76 (1.6), 65 (11), 63 (2), 51 (4.4), 50 (1.9), 46 (21) (NO <sub>2</sub> <sup>+</sup> ), 41 (1.6), 39 (3.7), 30 (100) (NO <sup>+</sup> )

ions Φ<sub>1</sub>–Φ<sub>6</sub> (26–100 rel%) with charge localization on both parts of the molecule (see table).

Fragmentation of oxadiazoles I–V involving elimination of the nitromethyl substituent (path *d*) afforded the peak of ion Φ<sub>7</sub> of medium intensity (21–35 rel%). This process occurred apparently due to good

stabilization of the cation center of ion [*M*–R]<sup>+</sup> ensured by the conjugation with the p-electron system of the benzene ring. Ions of the primary dissociation Φ<sub>1</sub>–Φ<sub>7</sub> suffer further fragmentation along the pathways characteristic of nitriles, diazo compounds, and nitro compounds [14]. However despite the common frag-



mentation character of oxadiazoles **I-V** the accumulation of nitro groups in the nitromethyl substituent results in appearance of additional concurrent fragmentation paths of molecular ions. Thus the mass spectra of compounds **I, II, and V** are distinguished by appearance of ion  $\text{NO}^+$  peak with  $m/z$  30 (31–44 rel%), and of ion  $\text{NO}_2^+$  peak with  $m/z$  46 (73–86 rel%) apparently originating from more intense fragmentation process involving nitro groups characteristic of polynitromethanes [15]. At the same time peaks of these ions in the spectra of compounds **III and IV** are of low intensity (1–14 rel%).

A similar pattern of the primary fragmentation is also observed for 4-(dinitromethyl)-1,2,3-triazoles **VI, IX** and **VII, X** isomeric with respect to location of the N-methyl group (Scheme 2). Peaks of molecular ions are lacking, and maximal remains the peak of  $\text{NO}^+$  ion with  $m/z$  30 (72–100 rel%).

Peaks of ions containing fragments of triazole ring are also observed:  $\Phi_1$  with  $m/z$  186 (1 and 2 rel%) for compounds **VI and IX**, and with  $m/z$  213 (0.2 and 3 rel%) for compounds **VII and X**, and also a peak  $\Phi_2$  of ion  $[M - 2\text{NO}_2 - \text{NO}]^+$  with  $m/z$  110 (0.1–3 rel%). Although the intensity of these peaks in the mass spectra of pairs of compounds **VI, IX** and **VII, X** is different, they are hardly suitable for isomers identification because of low

overall intensity. The solution of this problem may be attained by comparison in the mass spectra of isomers **VI and IX** of peak  $\Phi_3$  from ion  $[\text{N}_2\text{CH}_3]^+$  with  $m/z$  43. Its intensity in the mass spectrum of compound **IX** amounts to 21 rel% and in that of compound **VI** to 1.4 rel%. Large difference in the intensity of the peak in the spectra of isomers **VI and IX** is due to the difference in their initial structures and consequently in the structure of their molecular and fragment ions. This fragmentation path is almost improbable for compound **VI**.


The identification of isomers **VII and X** can be performed using as analytical peaks those of ions  $[\text{HCN-Me}]^+$  with  $m/z$  42 and  $[\text{N}_2\text{-Me}]^+$  with  $m/z$  43. In the mass spectrum of isomer **VII** peak of ion with  $m/z$  43 is of intensity 6 rel% whereas the peak of ion with  $m/z$  42 is the most abundant (100 rel%). It is presumable that the ion of  $m/z$  42 forms at fragmentation of the triazole ring, and its most probable precursor is the ion  $[M - \text{NO}_2]^+$  although the formation of this ion from other precursors, e.g., from ion  $[M - \text{NO}_2 - \text{NO} - \text{CO}]^+$  with  $m/z$  155, cannot be excluded.

In the mass spectrum of compound **X** the peak of ion with  $m/z$  42 (2 rel%) is hardly observable, and the intensity of the ion peak of  $m/z$  43 is 27 rel%.



different stability of ions  $[M - \text{NO}_2]^+$  arising from isomers **VIII** and **XI**.

In the case of isomer **VIII** the carbocation site of the ion  $[M - \text{NO}_2]^+$  is conjugated with the  $\pi$ -electron system of benzene ring, but this conjugation is absent in the ion originating from isomer **XI** resulting in sharp difference in the pattern of mass spectra belonging to these compounds.



Mass spectra of azoles studied contain additionally a large number of ion peaks which may correspond to several empirical formulas. As a result a more detailed interpretation of the mass spectra is complicated.

## EXPERIMENTAL

Compounds under study were prepared by the following published procedures: compounds **I** and **II** [16]; compounds **III** and **IV** [17], compound **V** [18], compounds **VI**, **VII**, **IX**, and **X** [19], compounds **VIII** and **XI** [20].

Mass spectra were measured on GC-MS spectrometer Finnigan SSQ-7000 with direct input of sample, ionizing electrons energy 70 eV, vaporizer temperature 90–150°C.

The authors are deeply grateful to A.T. Lebedev and A.D. Misharev for recording mass spectra.

## REFERENCES

1. Mashkovskii, M.D., *Lekarstvennye sredstva* (Medicines), Moscow: Novaya Volna, 2002, vol. 1, p. 262.
2. Leandri, G., Maioli, L., and Ruzzier, L., *Boll. Sci. Fac.*

- Chim. Ind. Bologna*, 1957, vol. 15, p. 57; Pancechowska-Ksepko, D., Foks, H., Janowiec, M., and Zwolska-Kwiek, Z., *Acta Pol. Pharm.*, 1986, vol. 43, p. 211.
3. Croveti, A.J. and Von Esch, A.M., *J. Heterocyclic Chem.*, 1972, vol. 9, p. 435; Clapp, L.B., *Adv. Heterocycl. Chem.*, 1976, vol. 20, p. 65.
4. Eloy, F., *Fortsch. Chem. Forsch.*, 1965, vol. 4, p. 807.
5. Yakovleva, L.V. and Tyrkov, A.G., Abstracts of Papers, VII Mezhdunarodnaya nauchno-tehnicheskaya konferentsiya "Naukoemkie khimicheskie tekhnologii-2001" (7th Int. Sci. Techn. Conf. "Hightech Chemical Processing 2001"), Yaroslavl, 2001, p. 118.
6. Tyrkov, A.G., *Cand. Sci. (Chem.) Dissertation*, Leningrad, 1990, 20 p.
7. Tilley, J., Ramuz, H., Levitan, P., and Blount, J., *Helv. Chim. Acta*, 1980, vol. 63, p. 841.
8. Yarovenko, V.N., Shirinyan, V.Z., Zavarzin, I.V., and Krayushkin, M.M., *Izv. Akad. Nauk, SSSR, Ser. Khim.*, 1991, p. 2166.
9. Yonng, T.E. and Beidler, W.T., *J. Org. Chem.*, 1985, vol. 50, p. 1182.
10. Kelarev, V.I., Karakhanov, R.A., Gasanov, S.Sh., Polivin, Yu.N., and Mikaya, A.I., *Zh. Org. Khim.*, 1993, vol. 29, p. 763.
11. Kocevar, M., Stanovnik, B., and Tisler, M., *J. Heterocyclic Chem.*, 1982, vol. 19, p. 1397.
12. Nibbering, N. and de Boeyr, Th., *Org. Mass Spectrom.*, 1969, 2, p. 157.
13. Compennolle, F. and Dekeirel, M., *Org. Mass Spectrom.*, 1971, vol. 5, p. 427.
14. Budzikiewicz, H., Djerassi, C., and Williams, D.H., *Mass Spectrometry of Organic Compounds*, San-Francisco: Holden-Day, Inc., 1967, 690 p.
15. Saalfeld, F., Larkins, J., and Kaplan, L., *Org. Mass Spectrom.*, 1969, vol. 2, p. 213; Maquestiau, A., Haverbeke, J., and Flammang, R., *Org. Mass Spectrom.*, 1973, vol. 7, p. 271.
16. Tyrkov, A.G. and Resnyanskii, V.V., *Izv. Vuzov, Ser. Khim. i Khim. Tekhnol.*, 1994, vol. 37, p. 131.
17. Tyrkov, A.G. and Sukhenko, L.T., *Khim.-Farm. Zh.*, 2002, vol. 36, p. 14.
18. Ladyzhnikova, T.D., Altukhov, K.V., and Solov'ev, N.A., *Zh. Org. Khim.*, 1986, vol. 22, p. 2618.
19. Ladyzhnikova, T.D., Mel'nikov, A.A., Solov'ev, N.A., Tselinskii, I.V., and Altukhov, K.V., *Zh. Org. Khim.*, 1987, vol. 23, p. 2624.
20. Ladyzhnikova, T.D., Solov'ev, N.A., Altukhov, K.V., Perekalin, V.V., and Berkova, G.A., *Zh. Org. Khim.*, 1988, vol. 24, p. 644.